Drug regulator in India orders clinical trials of generics

01/21/2013 | BioSpectrum Asia

The Drug Controller General of India, which regulates the country's pharmaceuticals, has asked drugmakers to conduct clinical trials of all generic drugs and seek approval within 18 months. The move is in response to abuse of legal loopholes that enabled some companies to bypass DGCI and sell drugs with dangerous side effects, many of which are banned abroad.

View Full Article in:

BioSpectrum Asia

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA